Quarterly ResultMay 4, 2026, 04:08 PM
Tactile Medical Q1 Revenue +23% to $75.3M; Net Loss Narrows to $1.8M
AI Summary
Tactile Medical reported strong first-quarter 2026 financial results, with total revenue increasing 23% year-over-year to $75.3 million. The company significantly improved its profitability, narrowing its net loss to $1.8 million and achieving a positive Adjusted EBITDA of $3.7 million. Key business highlights included FDA 510(k) clearance for its next-generation AffloVest and the repurchase of $1.1 million in stock. Based on this performance, Tactile Medical raised its full-year 2026 revenue guidance to a range of $360 million to $368 million.
Key Highlights
- Total revenue increased 23% year-over-year to $75.3 million.
- Net loss narrowed to $1.8 million from $3.0 million in Q1 2025.
- Adjusted EBITDA was $3.7 million, up from a loss of $0.3 million in Q1 2025.
- Gross margin improved to 76.5% compared to 74% in Q1 2025.
- Repurchased $1.1 million of stock under its share repurchase program.
- Lymphedema product line revenue increased 23% to $62.2 million.
- Airway clearance product line revenue increased 22% to $13.0 million.
- Updated 2026 full-year revenue guidance to $360M-$368M (9%-12% growth).